Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» AbbVie
AbbVie
AbbVie shares rise on $1 bln investment in partnership with Alphabet-backed health company
Marketwatch
Tue, 06/26/18 - 10:09 am
AbbVie
Calico Life Sciences
Alphabet
drug development
After Rova-T bust, AbbVie plans new solid tumor assault, licensing next-gen CAR-T tech from Calibr
Endpoints
Mon, 06/25/18 - 12:45 pm
AbbVie
Rova-T
solid tumors
Calibr
CAR-T
Why is AbbVie’s tax rate so low? Humira patents cached in Bermuda: Reuters
Fierce Pharma
Wed, 06/20/18 - 07:10 pm
AbbVie
taxes
Bermuda
Humira
patents
5 Experimental New Drugs That Could Be Worth $47 Billion
Motley Fool
Wed, 06/20/18 - 09:26 am
GSK2857916
GSK
brolucizumab
Novartis
aducanumab
Biogen
upadacatinib
AbbVie
VX-659 + tezacaftor + ivacaftor
Vertex Pharmaceuticals
Bristol-Myers, AbbVie eye new use for myeloma drug Empliciti after phase 2 combo win
Fierce Pharma
Mon, 06/18/18 - 09:47 pm
Bristol-Myers Squibb
AbbVie
Empliciti
Multiple Myeloma
Humira's Sales Will Decline -- and It's Fantastic News for AbbVie
Motley Fool
Wed, 06/13/18 - 10:16 am
Humira
AbbVie
biosimilars
AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia
Endpoints
Mon, 06/11/18 - 09:17 am
AbbVie
Roche
Venclexta
Rituxan
CLL
chronic lymphocytic leukemia
3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate
Yahoo/Motley Fool
Sun, 06/10/18 - 10:59 am
AbbVie
Huimra
Upadacitinib
rheumatoid arthritis
AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024
Fierce Pharma
Fri, 06/8/18 - 09:48 am
Humira
AbbVie
Keytruda
Merck
Revlimid
Celgene
Opdivo
Bristol-Myers Squibb
AbbVie to submit upadacitinib to FDA after 5th trial win
Fierce Pharma
Wed, 06/6/18 - 11:31 am
AbbVie
Upadacitinib
rheumatoid arthritis
FDA
JAK inhibitors
Two drugs in the pipeline representing unique marketing challenges
Medical Marketing and Media
Tue, 06/5/18 - 10:37 pm
valrox
Biomarin
hepatitis A
risankizumab
AbbVie
Boehringer Ingelheim
psoriasis
#ASCO18: AbbVie convinces one top analyst that its $6B ‘megablockbuster’ Rova-T is worthless
Endpoints
Tue, 06/5/18 - 12:09 pm
AbbVie
Rova-T
ASCO 2018
antibody-drug conjugate
ASCO18: AbbVie blood cancer combo off to a strong start in Phase 2
Biopharma Dive
Mon, 06/4/18 - 09:37 am
AbbVie
Imbruvica
Venclexta
chronic lymphocytic leukemia
small lymphocytic lymphoma
ASCO 2018
How Novartis, Insurers Are Taking Wind Out Of AbbVie's Sales
Investors Business Daily
Fri, 06/1/18 - 10:43 pm
AbbVie
Novartis
Humira
biosimilars
Europe
CHMP
AbbVie eyes Imbruvica expansion in CLL as Gazyva pairing hits its marks
Fierce Pharma
Thu, 05/24/18 - 05:44 pm
AbbVie
Imbruvica
CLL
Gazyva
Up-and-coming Pfizer, AbbVie drugs set to threaten Amgen, Celgene: analyst
Fierce Pharma
Wed, 05/23/18 - 09:54 am
Pfizer
Xeljanz
AbbVie
Upadacitinib
JAK inhibitors
Amgen
Enbrel
Celgene
FDA Clears IND for CytomX's CX-2029, a CD71-Directed Probody Therapeutic
CP Wire
Tue, 05/22/18 - 09:53 am
CytomX
AbbVie
CX-2029
cancer
FDA Clears IND for CytomX's CX-2029, a CD71-Directed Probody Therapeutic
Tue, 05/22/18 - 01:08 pm
CytomX
AbbVie
CX-2029
Amgen, AbbVie 'ahead of the crowd' in fighting payers' latest assault on copay coupons
Fierce Pharma
Mon, 05/21/18 - 09:18 am
copay coupons
Amgen
AbbVie
payers
AbbVie bows to pressure to keep cheaper Imbruvica formula on the market
Fierce Pharma
Wed, 05/16/18 - 06:57 pm
AbbVie
Imbruvica
Pages
« first
‹ previous
…
34
35
36
37
38
39
40
41
42
…
next ›
last »